BioCentury | Apr 15, 2020
Emerging Company Profile

Backed by Third Rock-led syndicate, MOMA seeks new ATP-powered targets by interrogating 'molecular machines'

...the clinic. MOMA's founders include Brandeis University professor Dorothee Kern, University of California Berkeley professor Eva...
...of technology: In-house Disease focus: Cancer, inflammation Clinical status: Preclinical Founded: 2020 by Dorothee Kern, Eva...
BioCentury | Apr 3, 2020
Distillery Therapeutics

IRE1 activation to treat cystic fibrosis and Pendred syndrome

...ERN1; IRE1A); cystic fibrosis transmembrane conductance regulator (CFTR); solute carrier family 26 member 4 (SLC26A4; EVA...
BioCentury | Feb 12, 2019
Company News

Management tracks: Sanofi, Alexion, bluebird

...UBS Securities. Autoimmune company Hansa Biopharma AB (SSE:HNSA) hired Donato Spota as CFO. Spota succeeds Eva-Maria...
BioCentury | Dec 15, 2018
Product Development

Extending Immunocore’s runway

...seen major changes in its executive team. Forster’s departure was followed by that of CBO Eva-Lotta...
BioCentury | Nov 30, 2018
Company News

Immunocore, Genentech team up to bring soluble TCR therapy into clinic

...to the tumor (see "Strengthening the (Immuno)core" ). This year, former CEO Eliot Forster, CBO Eva-Lotta...
BioCentury | Nov 19, 2018
Company News

Immunocore, Genentech team up to bring soluble TCR therapy into clinic

...to the tumor (see "Strengthening the (Immuno)core" ). This year, former CEO Eliot Forster, CBO Eva-Lotta...
BioCentury | Sep 4, 2018
Financial News

Another C-suite departure at Immunocore

...Forster stepped down in February. Chief Commercial Officer Andrew Hotchkiss is interim CEO. Former CBO Eva-Lotta...
BioCentury | Jul 6, 2018
Company News

Management tracks: Goldman Sachs, Acceleron

...Pharmaceuticals Inc. (Cambridge, Mass.). Small molecule drug discovery company C4X Discovery Holdings plc (LSE:C4XD) appointed Eva-Lotta...
BioCentury | Jun 20, 2018
Distillery Techniques

Drug platforms

...4, 2018 doi:10.1038/s41467-018-04609-7 CONTACT: Stephan Riesenberg, Max Planck Institute for Evolutionary Anthropology, Leipzig, Germany email: stephan.riesenberg@eva.mpg.de Hongjiang...
BioCentury | Feb 28, 2018
Distillery Therapeutics

Infectious disease

INDICATION: Enterovirus In vitro and cell culture studies identified enterovirus protein 2C inhibitors that could help treat enteroviral infections. Chemical synthesis of pyrazolopyridine carboxamide analogs and in vitro testing in viral growth assays yielded at...
Items per page:
1 - 10 of 49
BioCentury | Apr 15, 2020
Emerging Company Profile

Backed by Third Rock-led syndicate, MOMA seeks new ATP-powered targets by interrogating 'molecular machines'

...the clinic. MOMA's founders include Brandeis University professor Dorothee Kern, University of California Berkeley professor Eva...
...of technology: In-house Disease focus: Cancer, inflammation Clinical status: Preclinical Founded: 2020 by Dorothee Kern, Eva...
BioCentury | Apr 3, 2020
Distillery Therapeutics

IRE1 activation to treat cystic fibrosis and Pendred syndrome

...ERN1; IRE1A); cystic fibrosis transmembrane conductance regulator (CFTR); solute carrier family 26 member 4 (SLC26A4; EVA...
BioCentury | Feb 12, 2019
Company News

Management tracks: Sanofi, Alexion, bluebird

...UBS Securities. Autoimmune company Hansa Biopharma AB (SSE:HNSA) hired Donato Spota as CFO. Spota succeeds Eva-Maria...
BioCentury | Dec 15, 2018
Product Development

Extending Immunocore’s runway

...seen major changes in its executive team. Forster’s departure was followed by that of CBO Eva-Lotta...
BioCentury | Nov 30, 2018
Company News

Immunocore, Genentech team up to bring soluble TCR therapy into clinic

...to the tumor (see "Strengthening the (Immuno)core" ). This year, former CEO Eliot Forster, CBO Eva-Lotta...
BioCentury | Nov 19, 2018
Company News

Immunocore, Genentech team up to bring soluble TCR therapy into clinic

...to the tumor (see "Strengthening the (Immuno)core" ). This year, former CEO Eliot Forster, CBO Eva-Lotta...
BioCentury | Sep 4, 2018
Financial News

Another C-suite departure at Immunocore

...Forster stepped down in February. Chief Commercial Officer Andrew Hotchkiss is interim CEO. Former CBO Eva-Lotta...
BioCentury | Jul 6, 2018
Company News

Management tracks: Goldman Sachs, Acceleron

...Pharmaceuticals Inc. (Cambridge, Mass.). Small molecule drug discovery company C4X Discovery Holdings plc (LSE:C4XD) appointed Eva-Lotta...
BioCentury | Jun 20, 2018
Distillery Techniques

Drug platforms

...4, 2018 doi:10.1038/s41467-018-04609-7 CONTACT: Stephan Riesenberg, Max Planck Institute for Evolutionary Anthropology, Leipzig, Germany email: stephan.riesenberg@eva.mpg.de Hongjiang...
BioCentury | Feb 28, 2018
Distillery Therapeutics

Infectious disease

INDICATION: Enterovirus In vitro and cell culture studies identified enterovirus protein 2C inhibitors that could help treat enteroviral infections. Chemical synthesis of pyrazolopyridine carboxamide analogs and in vitro testing in viral growth assays yielded at...
Items per page:
1 - 10 of 49